Search Results - highly

6 Results

Sort By:

Mononegavirales Vectors Expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use...

Published: 7/25/2024 | Inventor(s): Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir

Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule

B. anthracis strains BH480; plasmids encoding anthrax edema factor (EF) variants pSJ136EFOS, pSJ 136EFA and pSJ 136EFR.

Published: 7/25/2024 | Inventor(s): Clinton Leysath, Stephen Leppla

Keywords(s): ADENYLATE, Are, CYCLASE, DD1XXX, Dependent, Edema, factor, Having, Highly, Highlydependent, Listed LPM Soukas as of 4/15/2015, N-END, Post LPM Assignment Set 20150420, Potencies, Pre LPM working set 20150418, RM, RULE, That, VARIANTS, WIXXXX

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Infectious Disease

Mononegavirales Vectors expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not...

Published: 7/25/2024 | Inventor(s): Peter Collins, Ursula Buchholz, Linda Brock, Shirin Munir

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease

N6, A Novel, Broad, Highly Potent HIV-specific Antibody

This is a new antibody coming out of NIAID’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment...

Published: 7/25/2024 | Inventor(s): Jinghe Huang, Byong Kang, John Mascola, Elise Ishida, Tongqing Zhou, Anqi Zheng, Peter Kwong, Mark Connors

Keywords(s): ANTIBODY, bNAb, Broad, Highly, HIV-soecific, HIV-Specific, Listed LPM Thalhammer-Reyero as of 4/15/2015, N6, Novel, Ootent, Post LPM Assignment Set 20150420, POTENT, Pre LPM working set 20150418

Category(s): Collaboration Sought > Collaboration

Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease

This technology is for compositions and methods for diagnosis of Lyme disease. Currently, Lyme disease is diagnosed by clinical exam and a history of exposure to endemic regions. Although, laboratory tests may aid diagnosis, the best tests currently available are slow and labor intensive and require understanding of the test, and infection stage....

Published: 7/25/2024 | Inventor(s): Adriana Marques, Michael Iadarola, Peter Burbelo

Keywords(s): ANTIBODY, Borreliosis, DAXXXX, Detection, Disease, DXXXXX, Highly, Listed LPM Fenn as of 4/15/2015, LYME, Lyme Disease, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, QUANTITATIVE, SENSITIVE, SIMPLE, VJXXXX, WBXXXX

Category(s): TherapeuticArea > Infectious Disease, Application > Diagnostics

Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers

The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...

Published: 7/25/2024 | Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner

Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology